Genocea Biosciences, Inc. GNCAQ
OTC PK
| 03/31/2022 | 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | |
|---|---|---|---|---|---|
| Revenue | 1.91M | 1.64M | 1.64M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.91M | 1.64M | 1.64M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.91M | 1.64M | 1.64M | -- | -- |
| SG&A Expenses | 14.64M | 14.71M | 15.47M | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.46M | 54.83M | 52.04M | -- | -- |
| Operating Income | -56.54M | -53.19M | -50.40M | -- | -- |
| Income Before Tax | -37.19M | -33.20M | -34.90M | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.19 | -33.20 | -34.90 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.19M | -33.20M | -34.90M | -- | -- |
| EBIT | -56.54M | -53.19M | -50.40M | -- | -- |
| EBITDA | -55.16M | -51.83M | -49.11M | -- | -- |
| EPS Basic | -0.53 | -0.49 | -0.53 | -- | -- |
| Normalized Basic EPS | -0.34 | -0.31 | -0.33 | -- | -- |
| EPS Diluted | -0.67 | -0.63 | -0.67 | -- | -- |
| Normalized Diluted EPS | -0.34 | -0.31 | -0.33 | -- | -- |
| Average Basic Shares Outstanding | 279.30M | 274.34M | 268.56M | -- | -- |
| Average Diluted Shares Outstanding | 281.53M | 276.57M | 270.79M | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |